Analytical Data
-
Gene name
LF2
- Application
-
Alternative Names
LF2；H；HSC；Galactoside alpha-(1.2)-fucosyltransferase 1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P0C725
-
Expression Region
1-429aa
-
AA Sequence
MAEAYPGGAHAALASRRSSFRNSLRRLRPTEKPDTSFMRGVWKYEIFPSYVRVTNKQVLQLDAQCQELPPCPSVGQILSFKLPSFSFNTTTYGSRYFTVAFLFFGAEDNEVFLKPFFVMHSDQDIVLSVLNPRSLFIEKGKFTWYIVPIRLVKNPYLYLQILPGQSDIQLTRSCTQSGDKLNTSEPQIFLSGSPVTSQDECLPYLLAQHTPPFLKSYARIHTFPGKVCPVNAIRRGKGYVRVSVDTPDLKREGPLNVKVGMTLLDDVIIAFRYNPYPKSHWRWDGESTDIRYFGSPVIIPPNFITELEYNNTYEAPLSSKITAVVVSHSSNPVFYVYPQEWKPGQTLKLTVRNISNNPITIVTGQSMAQAFFIYAGDPSISTIMRRYIQRQGCALTLPGNIVVESSSLPTFERINKTFNGNIVASEGTL
-
Molecular Weight
53.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Recombinant LF2 protein research has gained significant attention due to its potential applications in various biotechnological and therapeutic fields. LF2, derived from Legionella pneumophila, is a key virulence factor that plays a crucial role in the pathogenesis of legionellosis, a severe form of pneumonia. Understanding and characterizing this protein can provide insights into the molecular mechanisms of bacterial invasion and immune evasion. Researchers are particularly interested in LF2 for its ability to interact with host cellular pathways, thereby facilitating the development of new strategies for vaccine formulation and antimicrobial therapies. Additionally, the ability to produce LF2 through recombinant DNA technology allows for the exploration of its functional properties in a controlled laboratory setting, paving the way for dissecting its role in host-pathogen interactions. As a result, recombinant LF2 protein serves as a valuable tool in uncovering the complexities of bacterial infections and holds promise for innovations in clinical treatments and vaccine development. This underscores the importance of LF2 not only in understanding bacterial pathogenesis but also in addressing public health challenges associated with Legionella infections.
